PubMed Health⌕ Search

PubMed · 14683108

Evidence for B-->phiphiK.

Abstract

We report evidence for the decay mode B-->phiphiK based on an analysis of 78 fb(-1) of data collected with the Belle detector at KEKB. This is the first example of a b-->sssss transition. The branching fraction for this decay is measured to be B(B+/--->phiphiK+/-)=(2.6(+1.1)(-0.9)+/-0.3)x10(-6) for a phiphi invariant mass below 2.85 GeV/c(2). Results for other related charmonium decay modes are also reported.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H-C Huang, K Abe, T Abe, I Adachi, H Aihara, M Akatsu, T Aso, V Aulchenko, T Aushev, A M Bakich, Y Ban, E Banas, A Bay, I Bedny, P K Behera, I Bizjak, A Bondar, A Bozek, M Bracko, T E Browder, B C K Casey, P Chang, Y Chao, K-F Chen, B G Cheon, R Chistov, Y Choi, Y K Choi, M Danilov, L Y Dong, A Drutskoy, S Eidelman, V Eiges, Y Enari, C Fukunaga, N Gabyshev, A Garmash, T Gershon, B Golob, R Guo, J Haba, F Handa, T Hara, N C Hastings, H Hayashii, M Hazumi, L Hinz, T Hokuue, Y Hoshi, W-S Hou, Y B Hsiung, Y Igarashi, T Iijima, K Inami, A Ishikawa, R Itoh, Y Iwasaki, H K Jang, J H Kang, J S Kang, P Kapusta, N Katayama, H Kawai, N Kawamura, T Kawasaki, H Kichimi, D W Kim, H J Kim, Hyunwoo Kim, J H Kim, K Kinoshita, P Koppenburg, S Korpar, P Krizan, P Krokovny, R Kulasiri, S Kumar, Y-J Kwon, G Leder, S H Lee, T Lesiak, J Li, A Limosani, S-W Lin, D Liventsev, J MacNaughton, G Majumder, F Mandl, D Marlow, H Matsumoto, T Matsumoto, W Mitaroff, H Miyata, G R Moloney, T Mori, T Nagamine, Y Nagasaka, T Nakadaira, E Nakano, M Nakao. 2003-12-10. Evidence for B-->phiphiK.. https://doi.org/10.1103/physrevlett.91.241802

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗